Qiagen NV
QGEN,
201%
Shares rose in the extended session on Wednesday after the Netherlands-based medical diagnostics company said it would start selling a portable COVID-19 test in the United States. Qiagen shares rose 4% hours later, after a 09% high in the regular session to close at $ 46 51 The company called the « SARS-CoV-2 Antigen Test QIAreach » said the test could treat up to 30 swab samples to detect SARS antigens- CoV-2, the virus that causes COVID-19, in people who have it The virus takes up to 15 minutes The test was developed by Qiagen in partnership with Australian digital diagnostic company Ellume Qiagen said that the QIAreach program « will be of particular value when introducing vaccines »
Wallace Witkovsky came to MarketWatch from the Associated Press in New York, where he was a business reporter specializing in pharmaceutical companies who had previously worked on trade publications covering the pharmaceutical and medical device industry since 1998 based in San Francisco, focusing on UX Stocks, affiliated with Wally on Twitter: @wmwitkowski
By using this site you agree to
Subscriber Agreement Terms of Use of &,
Privacy Notice f
Cookie Notice
Daily data provided by FACTSET subject to terms of use
Historical and current end-of-day data provided by FACTSET
All quotes are at the local exchange time
UX real-time selling data. Stock prices reflect trades reported through Nasdaq only
Daily data is delayed at least 15 minutes or as per exchange requirements
Rapid Antigen Test, Qiagen, Severe Acute Respiratory Syndrome, NYSE: QGEN, Stock
World News – CA – Qiagen stock rises in announced COVID-19 test
Related Headline :
– Qiagen Stock Rises in COVID- 19 Advertiser
– QIAGEN launches the SARS Portable Digital Antigen Test- CoV-2 can accurately analyze more than 30 samples per hour
– Qiagen (QGEN) SARS launches portable digital COV-2 antigen test
– Qiagen launches SARS-CoV-2 rapid antigen test Mobile
